SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Become the best at Discussion: 6 Procedures for Progress - 2Figure out How to Remain Persuaded During Your Internet based Degree Program
- 3Winter virus season so far is not too bad, but doctors worry about suffering to come
- 4Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- 5The Latest: Fueling begins as NASA aims to send 1st crew to the moon in 53 years
- Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- Holiday season sees uptick in norovirus cases, according to CDC
- Well informed: How to Take full advantage of Your Gadgets
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- CPA Canada appoints eight directors as new governance model takes effect
- Vote in favor of your Favored Kind of Scarf
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
